{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-036614","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.995845+00:00","generated_at":"2026-06-22T09:35:00.891553+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TransMedics Q3 revenue $25.7M (+378% YoY); 2022 guidance raised to $80-85M","bullets":["Net revenue $25.7M including $1.4M favorable adjustment; ex-adjustment $24.3M (+349% YoY).","Full-year 2022 revenue guidance raised to $80-85M (ex-adjustment) vs prior $67-75M.","Net loss narrowed to $7.4M from $13.0M in Q3 2021; cash and equivalents $204.5M.","National OCS Program (NOP) drove ~90% of US revenue; public offering netted ~$140M.","Gross margin 71% vs 70% a year ago; operating expenses $23.7M, up from $15.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-036614","json":"https://secwatch.observer/filing/0001564590-22-036614.json","markdown":"https://secwatch.observer/filing/0001564590-22-036614.md","text":"https://secwatch.observer/filing/0001564590-22-036614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/0001564590-22-036614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/tmdx-8k_20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:35:00.891553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa5fb0079c7470a432acccdf05af8a2221d7ddcb","claim":"TransMedics Group, Inc. reported full year 2022 results: revenue $80 million to $85 million. Guidance raised.","evidence_excerpt":"TransMedics is updating full year 2022 revenue to be in the range of $80 million to $85 million, excluding the $1.4 million favorable change in estimate for contra revenue, which represents 164% to 181% growth compared to the company’s prior year revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/0001564590-22-036614-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$80 million to $85 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"b1ffb398d5acf3780fe638d54537d6ecf4e72fe0","claim":"TransMedics Group, Inc. reported the quarter ended September 30, 2022 results: revenue $25.7 million, net income $7.4 million.","evidence_excerpt":"Net revenue for the third quarter of 2022 was $25.7 million, a 378% increase compared to $5.4 million in the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/0001564590-22-036614-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$25.7 million"},{"label":"Net income","value":"$7.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}